To hear about similar clinical trials, please enter your email below
Trial Title:
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
NCT ID:
NCT00373347
Condition:
Liver Cancer
Conditions: Official terms:
Carcinoma, Hepatocellular
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
The purpose of this study is to identify blood markers that have the ability to diagnose
liver cancer with improved accuracy, so that it can be used alone or in conjunction with
alpha-feto protein (AFP)
Detailed description:
Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The
currently used blood marker for the clinical diagnosis of liver cancer is alpha-feto
protein (AFP), which misses 40-60% of patients with liver cancer because it lacks
sufficient specificity and sensitivity. The purpose of this study is to identify blood
markers that have the ability to diagnose liver cancer with improved accuracy, so that it
can be used alone or in conjunction with AFP. The aim of this study is to identify new
blood markers of liver cancer that can be used to increase the rate of accurate diagnosis
of this malignancy.
Criteria for eligibility:
Study pop:
Patients diagnosed with liver cancer
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated
with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
- Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma,
or nodular hyperplasia.
- Patients with hepatitis B or hepatitis C viral infections not associated with liver
cancer.
Exclusion Criteria:
-Patients will be excluded if, upon looking through their medical records, information
required for data analysis are missing.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Stanford University School of Medicine
Address:
City:
Stanford
Zip:
94305
Country:
United States
Status:
Recruiting
Contact:
Last name:
Mei-Sze Chua
Phone:
650-724-3525
Email:
mchua@stanford.edu
Contact backup:
Last name:
Cancer Clinical Trials Office
Phone:
(650) 498-7061
Investigator:
Last name:
Samuel So
Email:
Principal Investigator
Start date:
November 2004
Completion date:
December 2025
Lead sponsor:
Agency:
Stanford University
Agency class:
Other
Source:
Stanford University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT00373347
